Tacrolimus monohydrateCAS# 109581-93-3 |
- Cefditoren Pivoxil
Catalog No.:BCC4898
CAS No.:117467-28-4
- Balofloxacin
Catalog No.:BCC4892
CAS No.:127294-70-6
- Pefloxacin Mesylate Dihydrate
Catalog No.:BCC5089
CAS No.:149676-40-4
- Tinidazole
Catalog No.:BCC4866
CAS No.:19387-91-8
- Toltrazuril
Catalog No.:BCC4870
CAS No.:69004-03-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 109581-93-3 | SDF | Download SDF |
| PubChem ID | 5282315 | Appearance | Powder |
| Formula | C44H71NO13 | M.Wt | 822.03 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Fujimycin monohydrate; FR900506 monohydrate; FK506 monohydrate;Tacrolimus Hydrate | ||
| Solubility | DMSO : ≥ 100 mg/mL (121.65 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone;hydrate | ||
| SMILES | CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC.O | ||
| Standard InChIKey | NWJQLQGQZSIBAF-MLAUYUEBSA-N | ||
| Standard InChI | InChI=1S/C44H69NO12.H2O/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7;/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3;1H2/b25-19+,27-21+;/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Tacrolimus monohydrate Dilution Calculator
Tacrolimus monohydrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.2165 mL | 6.0825 mL | 12.165 mL | 24.33 mL | 30.4125 mL |
| 5 mM | 0.2433 mL | 1.2165 mL | 2.433 mL | 4.866 mL | 6.0825 mL |
| 10 mM | 0.1217 mL | 0.6083 mL | 1.2165 mL | 2.433 mL | 3.0413 mL |
| 50 mM | 0.0243 mL | 0.1217 mL | 0.2433 mL | 0.4866 mL | 0.6083 mL |
| 100 mM | 0.0122 mL | 0.0608 mL | 0.1217 mL | 0.2433 mL | 0.3041 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Tacrolimus monohydrate binds to FK506 binding protein (FKBP). This complex inhibits calcineurin phosphatase (PP2B). Tacrolimus monohydrate is a mTOR-independent autophagy inducer.
In Vitro:Tacrolimus (FK506) inhibits calcium-dependent events, such as IL-2 gene transcription, NO synthase activation, cell degranulation, and apoptosis. Tacrolimus also potentiates the actions of glucocorticoids and progesterone by binding to FKBPs contained within the hormone receptor complex, preventing degradation. The agent may enhance expression of the TGFβ-1 gene in a fashion analogous to that demonstrated for CsA. T cell proliferation in response to ligation of the T cell receptor is inhibited by Tacrolimus[1]. Treatment with a low concentration of Tacrolimus (FK506,10 μg/L) does not significantly affect the proliferation of MH3924A cells (P=0.135). Upon treatment with higher concentrations of Tacrolimus (100-1,000 μg/L), the proliferation of MH3924A cells is significantly enhanced (P<0.01). Treatment with AMD3100 at any concentration (10, 50 or 100 μg/L), has no obvious effect on MH3924A cell proliferation (P>0.05). However, when different concentrations of AMD3100 are combined with 100 μg/L Tacrolimus, the in vitro proliferation of MH3924A cells is increased (P<0.01)[3].
In Vivo:The therapeutic effect of Tacrolimus is investigated on progression and perpetuation of colitis by administering Tacrolimus to Dextran sulfate sodium (DSS)-treated mice from Days 10 to 16 or to 23. At Days 17 and 24, colon length is significantly shortened, and colon weight is significantly higher in DSS-treated control animals than in normal animals. In addition, colon weight per unit length in the control group is more than twice that in the normal group. While both 7 and 14 d treatment with Tacrolimus significantly suppresses increases in colon weight per unit length in DSS-treated animals compared with the control group, this treatment does not actually restore the colon shortening. In addition, this inhibitory effect of Tacrolimus on increases in colon weight per unit length is more pronounced with 14-d than 7-d treatment, as shown by the inhibitory percentages (59% vs. 28%)[4].
- RX 821002 hydrochloride
Catalog No.:BCC7021
CAS No.:109544-45-8
- CCT137690
Catalog No.:BCC2188
CAS No.:1095382-05-0
- ARQ 621
Catalog No.:BCC6534
CAS No.:1095253-39-6
- Rac1 Inhibitor W56
Catalog No.:BCC5886
CAS No.:1095179-01-3
- PF-04449913
Catalog No.:BCC5154
CAS No.:1095173-27-5
- JNJ-31020028
Catalog No.:BCC5516
CAS No.:1094873-14-9
- 3'-Methyl-4-O-methylhelichrysetin
Catalog No.:BCN4062
CAS No.:109471-13-8
- BIX 02189
Catalog No.:BCC2549
CAS No.:1094614-85-3
- BIX 02188
Catalog No.:BCC2550
CAS No.:1094614-84-2
- Fmoc-His(Trt)-OPfp
Catalog No.:BCC3502
CAS No.:109434-24-4
- Fmoc-Orn(Boc)-OH
Catalog No.:BCC3533
CAS No.:109425-55-0
- Fmoc-His(Trt)-OH
Catalog No.:BCC3501
CAS No.:109425-51-6
- Pinocembrin 7-acetate
Catalog No.:BCN5887
CAS No.:109592-60-1
- Topazolin
Catalog No.:BCN6833
CAS No.:109605-79-0
- Neocryptotanshinone
Catalog No.:BCN3158
CAS No.:109664-02-0
- SPK-601
Catalog No.:BCC1961
CAS No.:1096687-52-3
- MLN 2480
Catalog No.:BCC1771
CAS No.:1096708-71-2
- Murraol
Catalog No.:BCN5888
CAS No.:109741-38-0
- cis-Dehydroosthol
Catalog No.:BCN4735
CAS No.:109741-40-4
- 8 beta-(4-Acetoxy-5-hydroxytigloyloxy)costunolide
Catalog No.:BCN7123
CAS No.:109770-86-7
- Homopahutoxin
Catalog No.:BCN1812
CAS No.:109777-68-6
- 9R-10alpha-Hydroxyepigambogic acid
Catalog No.:BCN3079
CAS No.:1097882-33-1
- ASP3026
Catalog No.:BCC1372
CAS No.:1097917-15-1
- Harmalidine
Catalog No.:BCN5889
CAS No.:109794-97-0
Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend SF PH4 oral suspensions.[Pubmed:27209697]
Pharmazie. 2016 Apr;71(4):185-91.
A challenge with compounding oral liquid formulations is the limited availability of data to support the physical, chemical and microbiological stability of the formulation. This poses a patient safety concern and a risk for medication errors. The objective of this study was to evaluate the compatibility of the following active pharmaceutical ingredients (APIs) in 10 oral suspensions, using SyrSpend SF PH4 (liquid) as the suspending vehicle: cholecalciferol 50,000 IU/mL, haloperidol 0.5 mg/mL, imipramine hydrochloride 5.0 mg/mL, levodopa/carbidopa 5.0/1.25 mg/mL, lorazepam 1.0 mg/mL, minocycline hydrochloride 10.0 mg/mL, Tacrolimus monohydrate 1.0 mg/mL, terbinafine 25.0 mg/mL, tramadol hydrochloride 10.0 mg/mL and valsartan 4.0 mg/mL. The suspensions were stored both refrigerated (2 - 8 degrees C) and at controlled room temperature (20 - 25 degrees C). This is the first stability study for these APIs in SyrSpend SF PH4 (liquid). Further, the stability of haloperidol,ilmipramine hydrochloride, minocycline, and valsartan in oral suspension has not been previously reported in the literature. Compatibility was assessed by measuring percent recovery at varying time points throughout a 90 days period. Quantification of the APIs was performed by high performance liquid chromatography (HPLC-UV). Given the percentage of recovery of the APIs within the suspensions, the beyond-use date of the final preparations was found to be at least 90 days for most suspensions both refrigerated and at room temperature. Exceptions were: Minocycline hydrochloride at both storage temperatures (60 days), levodopa/carbidopa at room temperature (30 days), and lorazepam at room temperature (60 days). This suggests that compounded suspensions of APIs from different pharmacological classes in SyrSpend SF PH4 (liquid) are stable.
